Objective:To investigate the clinical efficacy and safety of domestic bortezomib in the treatment of patients with multiple myeloma (MM).Methods:The data of 60 MM patients treated with domestic bortezomib as the basic chemotherapy regimen in 5 medical centers of Qilu Hospital of Shandong University, Heze Municipal Hospital, Weifang People's Hospital, Binzhou Medical University Hospital, Zibo Central Hospital in Shandong Province from January 2018 to June 2019 were retrospectively analyzed, 52 of which were newly treated patients and 8 were relapsed and refractory patients. The patients received at least 2 courses of combined chemotherapy based on domestic bortezomib, and the efficacy was assessed and evaluated every 2 courses.Results:Follow-up until June 30, 2019 showed that some patients were unable to return to the hospital for regular treatment. All patients completed at least 2 courses of treatment, with an overall effective rate (ORR) of 76.7% (46/60); 42 patients completed 4 courses of treatment, with an ORR of 78.6% (33/42); 30 patients completed 6 courses of treatment, with an ORR of 86.7% (26/30); there was no significant difference in ORR of 2, 4 and 6 courses ( P > 0.05). The complete remission+very good partial remission rates of 2, 4 and 6 courses were 16.7% (10/60), 47.6% (20/42) and 66.7% (20/30), respectively, and the difference was statistically significant ( P < 0.01). During the treatment, the adverse events mainly included infection, peripheral neuropathy, herpes, digestive tract symptoms, hematologic toxicities and so on, which were light and moderate mostly, and most of them can be reversed. The total incidence of adverse events in patients who completed 2, 4 and 6 courses of treatment were 91.7% (55/60), 66.7% (28/42) and 36.7% (11/30), respectively. Conclusions:The domestic bortezomib-based chemotherapy regimens have good efficacy in the treatment of MM. The incidence of adverse events is similar to that of the original drug, and patients can tolerate the adverse events.

Objective: To analyze the clinical features, the efficacy of131I therapy and its effect on granulopoiesis in Graves′ hyperthyroidism(hyperthyroidism) patients with neutropenia. Methods: 144 hyperthyroidism patients were retrospectively studied after131I therapy, among which 42 cases(HT group) accompanied neutropenia due to hyperthyroidism itself, 52 cases(ATD group) appeared neutropenia after anti-thyroid drug(ATD)treatment, and the remaining 50 cases(control group) were hyperthyroidism patients with normal neutrophil count. The clinical features, the efficacy of131I treatment for hyperthyroidism and the change of neutrophil count after131I treatment were analyzed and compared in three groups. Results: Mild neutropenia was commoner in both the HT group and the ATD group. The curative rate of hyperthyroidism in the HT group, the ATD group and the control group were80. 95%, 84. 62% and 84. 00%, respectively. There was no significant difference in the efficacy of131I therapy among the three groups. Compared with the baseline value before treatment, neutrophil count increased in all three groups 2-4 weeks after131I treatment(allP<0. 05). The neutrophil recovery rates of the HT group and the ATD group were 61. 90% and 84. 62%, respectively. The ATD group had a higher recovery rate(P<0. 05). Conclusion Mild neutropenia is commoner in hyperthyroidism patients with neutropenia due to either hyperthyroidism itself or ATD treatment. Normative131I treatment for hyperthyroidism patients with neutropenia is safe and effective.